

The stamp is circular with the following text:  
U.S. PATENT & TRADEMARK OFFICE  
MAR 12 2004  
873-11000

**N THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re ~~Applicant:~~**

Yoram REITER

Serial No.: 10/073,300

Filed: February 13, 2002

## For: Single Chain Class I Major Histo-Compatibility Complexes

Group Art Unit: 1644

Attorney  
Docket: 02/23339

Examiner:

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

*Sol Sheinbein*  
Sol Sheinbein

Registration No. 25457

Date: March 8, 2004



Please type a plus sign (+) inside this box → +

Approved for use through 10/31/99 OMB 0651-00

Approved for use through 10/31/99 GMB 0031-003  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-96)

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → 

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number
				10/073,300
				Filing Date
				02/13/2002
				First Named Inventor
				Reiter
				Group Art Unit
				1644
				Examiner Name
Sheet	1	Of	2	Attorney Docket Number
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/PV/		Ojcius et al, "Dissociation of the Peptide-MHC Class I Complex Limits the Binding Rate of Exogenous Peptide", <i>J. Immunology</i> , 151(11):6020-6026, 1993		
↓		Parker et al, "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2", <i>J Immunol.</i> , 149(11):3580-7, 1992		
↓		Lone et al, "In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes", <i>J Immunother.</i> , 21(4):283-94, 1998.		
↓		Lee et al, "Functional cell surface expression by a recombinant single-chain class I major histocompatibility complex molecule with a cis-active beta 2-microglobulin domain", <i>Eur J Immunol.</i> , 24(11):2633-9, 1994		
↓		Kourilsky et al, "Immunological Issues in Vaccine Trials: T-Cell Responses", found in "Preclinical and Clinical Development of New Vaccines", Plotkin et al (eds), Karger, Basel, Vol. 95, pp. 117-124, 1998		
Examiner Signature	/F Pierre Vandervegt/			Date Considered 4/29/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Unique citation designation number. <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.